Study Summary
Evaluation of Sup19 CAR-T cells in cases where previous CD19-targeted therapy has failed or where CD19 Evaluation of Safety and Efficacy in the Treatment of Low-Grade Hematological Malignancies: A Prospective, Single-Arm Clinical Study Research
Want to learn more about this trial?
Request More InfoInterventions
Sup19 CAR-TBIOLOGICAL
The use of Sup19 CAR-T cells to treat hematologic malignancies with prior CD19-targeted therapy failure or CD19 weak expression aims to improve the relapse-free survival rate in patients with hematologic malignancies, providing a novel curative strategy for these patients.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Institute of Hematology, Chinese Academy of Medical Sciences & Hospital of Hematology, Chinese Academy of Medical Sciences | Tianjin | Tianjin Municipality | China |